Mri-Assisted high intensity focused ultrasound metastatic Liver Tumor Ablation (MALTA study) - MALTA

niversitair Medisch Centrum Utrecht0 个研究点目标入组 50 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•- At least 18 years old;
•- Able to give informed consent;
•- One or more metastatic liver tumor(s);
•- Target tumor is eligible for surgical resection;
•- Sufficient physical condition to undergo general anesthesia or deep sedation;
•- Waist circumference that allows positioning on the HIFU table-top inside the MR bore;
•- Based on a clinically available CT/MRI scan, the liver tumor is potentially accessible for MR-HIFU treatment (this relies on the judgment of the investigator and physicians).

•- Contra-indication for MRI scanning according to the hospital guidelines;
•- Contra-indication to injection of gadolinium-based contrast agent, including known prior allergic reaction to any contrast-agent, and renal failure (defined as GFR < 30mL/min/1.73m2);
•- Patients who prefer not to be informed about unexpected MRI findings;
•- Surgical clips or considerable scar tissue in the HIFU beam path;
•- Past or future other loco regional therapies for the same tumor (that is to be treated with MR-HIFU ablation) until the moment of surgical resection, such as (but not restricted to) RF ablation, microwave ablation, cryoablation, chemo-embolization, radio-embolization, or radiotherapy.

发起方

niversitair Medisch Centrum Utrecht